Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H24ClN3OS2.ClH |
Molecular Weight | 482.489 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ClC1=CC2=C(SC3=C(C=CC=C3)N2CCCN4CCC5(CC4)NC(=O)CS5)C=C1
InChI
InChIKey=JRSBQVOEILNXGS-UHFFFAOYSA-N
InChI=1S/C22H24ClN3OS2.ClH/c23-16-6-7-20-18(14-16)26(17-4-1-2-5-19(17)29-20)11-3-10-25-12-8-22(9-13-25)24-21(27)15-28-22;/h1-2,4-7,14H,3,8-13,15H2,(H,24,27);1H
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452 |
|||
Target ID: CHEMBL2331074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111088 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Diceplon Approved UseAntipsychotic |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Studies on psychotropic drugs. V. Pharmacological effects of 8-(3-(2-chloro-10-phenothiazinyl)propyl)-1-thia-4,8-diazaspiro(4,5) decan-3-one hydrochloride (APY-606)]. | 1970 Jul |
|
Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. | 1981 Feb |
|
High performance liquid chromatography/electrospray tandem mass spectrometry for phenothiazines with heavy side chains in whole blood. | 1999 |
|
Spiclomazine induces apoptosis associated with the suppression of cell viability, migration and invasion in pancreatic carcinoma cells. | 2013 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10567940
oral administration of 5-10 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452
Treatment with Clospirazine hydrochloride (spiclomazine) for 24 and 48 h resulted in a time and
dose-dependent growth reduction of CFPAC-1 and MIA PaCa-2 cell lines examined
by MTT assay. This small molecule inhibited the
cell growth to approximately 61.1+/-5.3%, 76.4+/-3.2% and
90.4+/-0.5% of control in CFPAC-1 cells, and 79.3+/-1.0%,
84.5+/-1.5% and 93.6+/-0.2% of control in MIA PaCa-2 cells at
the concentrations of 30, 40, and 50 mg/mL for 48 h, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
122820
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | |||
|
290956
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | |||
|
1648692
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | RxNorm | ||
|
m1088
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
N6B142V0U0
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | |||
|
DTXSID4023593
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | |||
|
27007-85-8
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY | |||
|
N6B142V0U0
Created by
admin on Sat Dec 16 04:28:56 GMT 2023 , Edited by admin on Sat Dec 16 04:28:56 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD